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Abstract
Tuberous sclerosis (TS) is a common autosomal-dominant disorder characterized by tumors of the skin, lung, brain,
and kidneys. Monotherapy with rapamycin however resulted in partial regression of tumors, implying the
involvement of additional pathways. We have previously implicated platelet-derived growth factor-BB in TS-related
tumorigenesis, thus providing a rationale for a combination of mTOR/PDGF blockade using rapamycin and imatinib.
Here, we test this combination using a well-established preclinical model of cutaneous tumorigenesis in TS,
tsc2ang1 cells derived from a skin tumor from a mouse heterozygous for tsc2. Treatment of tsc2ang1 cells with a
combination of rapamycin and imatinib led to an inhibition of proliferation compared with either vehicle treatment
or treatment with rapamycin or imatinib monotherapy. Combination therapy also led to a decrease in Akt
activation. Potent in vivo activity in animal experiments by combination therapy was noted, without toxicity to the
animals. Our findings provide a rationale for the combined use of rapamycin and imatinib, both FDA approved
drugs, for the treatment of TS.
Introduction
TS is a common autosomal-dominant disorder charac-
terized by the development of tumors of the brain, kid-
ney, skin and lung. The disorder is characterized by
mutations or deletions in one of two large genes, hamar-
tin (TSC1) and tuberin (TSC2). In addition, neuro-
developmental complications of TS, including seizures
and autism, lead to significant morbidity. While no strict
genotype-phenotype relationship has been established,
the disease is more severe in patients with tsc2 muta-
tions. Loss of heterozygosity (LOH), which deletes the
unaffected allele, is required for the development of
some neoplastic features of TS, including renal angio-
myolipomas, lymphangiomyomatosis, and skin lesions,
while LOH is not observed in brain tubers which often
cause epileptic foci [1]. Apart from deletions, there are
other mechanisms causing inactivation of tsc1 and tsc2.
The signaling pathways implicated in TS are complex.
A hotspot for mutations in tsc2 involves regions impli-
cated in controlling rheb, although multiple other signal-
ing pathways have also been linked to TS-related
neoplasia, including mTORC1, notch, p42/44 MAP kin-
ase, NFkB, and Akt [2-11]. Tuberin (TSC2) was weak or
absent in angiomyolipomas, but present in healthy kid-
ney, whereas, phosphorylated p70 S6 kinase and pS6
were present only in angiomyolipomas. Activation of a
mammalian target of rapamycin metabolic pathway in
tuberous sclerosis lesions, which contributes to their
growth [2]. The upregulation of mTORC1 observed in
neoplasms of patients with TS has served as a rationale
for recent use of mTOR inhibitor rapamycin (sirolimus)
to treat TS. Rapamycin treatment was shown to result in
partial regression of kidney, lung and skin lesions but
not complete disappearance of tumors. In addition,
tumor re-growth was observed upon cessation of ther-
apy, consistent with the known cytostatic rather than
cytotoxic effects of rapamycin. The use of mTOR inhibi-
tors is becoming increasingly accepted, especially for the
treatment in TSC [2,12,13]. These clinical findings
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TS-related tumors [14].
We have previously demonstrated that platelet-derived
growth factor β receptor (PDGFRβ) is present and active
in human and murine TS lesions [15-17]. Other groups
have demonstrated an inverse relationship between
mTOR activation and PDGFRβ levels in TS-derived cells
[18]. Therefore, we reasoned that mTOR blockade might
be compensated for by PDGF activation in vitro and
in vivo, and combined blockade might be more effica-
cious than rapamycin monotherapy. To test this idea, we
used the FDA-approved drug imatinib (gleevec) to treat
mouse tumors formed by implanted tsc2ang1 cells, iso-
lated from a cutaneous sarcoma that arose in a tsc2
heterozygous mouse and a well-validated model of TS-
related neoplasia. Imatinib functions as a specific inhibi-
tor of a number of tyrosine kinase enzymes leading to
downregulation of MMP-2 [19]. Currently, imatinib is
approved for chronic myelogenous leukemia carring
the bcr-abl translocation, as well as hypereosinophilic
syndrome and eosinophilic leukemia with the FIP1L1-
PDGFRα fusion kinase. Solid tumors for which imati-
nib is approved include c-kit positive gastrointestinal
stromal tumor and inoperable dermatofibrosarcoma
protuberans (www.gleevec.com). We demonstrate that
addition of imatinib to rapamycin decreases the levels
and phosphorylation of PDGFRβ. Consistent with this,
combination treatment resulted in a greatly decreased
phosphorylation of Akt, and Akt is a major determin-
ant of tumorigenesis in vivo. Finally, we show that the
combination of rapamycin and imatinib has a greater
antitumor effect compared to vehicle alone than either
rapamycin or imatinib compared to vehicle in vivo.
These findings provide a rationale for combination
therapy with rapamycin and imatinib in TS.
Results
Rapamycin and imatinib treatment inhibits TSC2 ang1 cell
proliferation
To assess if rapamycin and imatinib combination was
superior to either agent alone, we assessd their effects
on the proliferation of Tsc2 ang1 cells. Treatment of
cells for 72 h with rapamycin (5nM) or imatinib (10 μM)
alone reduced the level of proliferation significantly
compared with control (p=0.0006 for imatinib vs con-
trol, p=0.0076 for rapamycin vs control). However,
Figure 1 (A) Effect of rapamycin, imatinib or combination of imatinib and rapamycin on tsc2ang1 cell line proliferation. Cells were
treated with vehicle control (DMSO), rapamycin (5nM), imatinib (10 μM) or imatinib (10 μM)+rapamycin (5nM) (shown along X-axis) for 24 h
and counted using a Coulter counter. Treatment at each concentration was performed in triplicate. The Y-axis represents cell number.
(B) Downregulation of Phospho-PDGFR-β by combinational treatment; Tsc2ang1 cells were treated with DMSO, rapamycin5nM, imatinib10uM
or rapamycin5nM+imatinib10uM for 24 hours prior to harvest. Combination rapamycin+imatinib treatment inhibits the levels of
phospho- PDGFR-β (Tyr 1021).
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cantly better inhibition of proliferation (Figure 1a), com-
pared with control (p=0.0002). Combination of drugs
was significantly better than rapamycin alone
(p=0.0243), while imatinib vs combination did not reach
significance at p less than 0.05. Experiments were done
in triplicates for reproducibility.
Combination of rapamycin and imatinib inhibits PDGFRβ
activation inTsc2 ang1 cells
In view of the effects of rapamycin and imatinib combin-
ation on Tsc2Ang1 cell proliferation together with previ-
ous findings that mTOR inhibitor treatment of TS is
associated with increased PDGFRβ levels, we examined
the effects of imatinib and rapamycin or a combination
of these on PDGFRβ expression. Experiments were done
in triplicates for reproducibility. We tested imatinib
(10 μM), rapamycin (5nM) or their combination on the
levels of phosphorylated PDGFRβ (at Tyr-1009) in
Tsc2ang1cells. Combined treatment led to downregula-
tion of PDGFRβ phosphorylation, (Figure 1b).
Treatment with combination of rapamycin and imatinib
down regulates phosphoAkt473 protein levels in
Tsc2ang1 cells
To verify the effect of imatinib and rapamycin, as well
as combination therapy on the activation of Akt, we
treated Tsc2ang1 cells with imatinib (10 μM), rapamy-
cin (5 nM) or their combination and the levels of Akt
and p Akt were measured by densitometry scanning
of the signals on western blot membrane. Total levels
of Akt were unchanged by treatment and served as
loading controls. We found first that overall, treatment
with drug led to significantly decreased phospho Akt
compared to vehicle controls (p=0.0002, general linear
modeling). In addition, we found that treatment with
rapamycin and imatinib reduced the levels of pAkt
(Figure 2) and a significant reduction in the levels of
pAkt (p <0.0002) in imatinib+rapamycin treated cells
compared to vehicle control. The mean of combin-
ation treatment versus imatinib alone or rapamycin
alone also decreased. However, significance was only
observed when the combination treatment was com-
pared to rapamycin alone (p<0.0243) and not when
compared to imatinib alone (p<0.4273).
Matrix metalloproteinase analysis
Cell migration and invasion are fundamental compo-
nents of tumor cell invasion and neovascularization.
Matrix metalloproteinases (MMPs) are essential for suc-
cessful cell migration through extracellular matrix. In
order to determine the levels of MMPs in our samples,
conditioned media from equivalent numbers of
imatinib- or rapamycin-treated cells along with that of
control cells were collected and quantitatively analyzed
using monospecific ELISAs. MMP-2 levels in condi-
tioned media from tsc2ang1 cells treated with either
imatinib (p=.0243), rapamycin or combination treat-
ment with rapamycin and imatinib (p=.0092) were sig-
nificantly decreased compared to that of controls
(Figure 3). However, MMP-2 levels in the conditioned
media of cells treated with rapamycin (p=.0744) were
not significantly decreased compared to that of controls
consistent with previous reports [20]. Differences be-
tween rapamycin alone and combination therapy
trended toward significance (p=0.0744), and between
imatinib alone and combination (p=0.329), indicating
that imatinib has a more potent effect on MMP-2 activ-
ity than rapamycin. Moreover, no significant difference
Figure 2 blot analysis using Akt and pAkt were conducted
on Tsc2 ang1 cells treated with treated with DMSO,
rapamycin5nM, imatinib10uM or rapamycin5nM+
imatinib10uM for 24 hours. Cells were lysed and analyzed by
using antibodies specific for the total Akt and pAkt473.
Rapamycin+imatinib treatment downregulates pAkt levels
(p <0.0002). GAPDH was used as the loading control by using
monoclonal anti-GAPDH antibody. All treatment groups were
significant when compared to the vehicle control, Imatinib 10nM
(p<0.0006); Rapamycin 5nM (p<0.0076); Rapamycin 5nM+Imatinib
10nM (p<0.0002). However, the combinational therapy only show
significance against Rapamycin at 5nM (p<0.0243) and not Imatinib
at 10nM (p<0.4273).
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treatment groups and controls (data not shown).
In vivo tumorigenesis
Given the effects of combined treatment with imatinib
and rapamycin on cell proliferation as well as the ability
of this combination to reduce the levels of phospho-
PDGFRβ and phosphor-Akt, we assessed the effects of
this combination on tsc2ang1 tumorigenesis in vivo.
While each drug individually reduced the size of tumors
formed compared to vehicle control, combined treat-
ment with imatinib and rapamycin resulted in a nearly
complete abrogation of tumor growth (97% decrease in
tumor volume compared with control, p<0.0001)
(Figure 4). Tumor volume was significantly different in
comparison between control vs rapamycin/imatinib,
rapamycin vs rapamycin/imatinib, and imatinib vs rapa-
mycin/imatinib (p<0.05). There was no significant
Figure 3 MMP-2 ELISA analysis of conditioned media from tsc2ang1 cells treated with either rapamycin, imatinib or the combination
for 24 hours resulted in a decrease in the amount of MMP-2 produced in comparison to controls. MMP-2 levels in the tsc2ang1 cells
treated with imatinib only and imatinib+rapamycin were significantly decreased compared to that of controls.
Figure 4 Effect of rapamycin and imatinib on in vivo growth of tsc2ang1 xenografts in nude mice. The y axis represents tumor volume.
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Tumor volume comparing imatinib alone versus com-
bination was significantly different (p=0.0209), while
tumor volume between rapamycin alone and combin-
ation did not reach significance (p=0.19). Neither local
nor systemic toxicity was observed in any of the treat-
ment groups indicating that combined effective inhib-
ition of tumor growth is feasible with imatinib and
rapamycin with minimal toxicity.
Discussion
TS is a multisystem disorder characterized by benign
or malignant neoplasia, as well as autism and seizures.
No highly effective and long lasting therapy exists for
TS neoplasia. Renal lesions such as angiomyolipomas
may cause massive bleeding and compromise renal
function, often requiring a kidney transplant. Lym-
phangiomyomatosis, a neoplastic complication most
commonly seen in young women, can only be cured
by lung transplantation. Deforming skin lesions cause
significant psychological distress [21]. Finally, brain
tumors such as subependymal giant cell astrocytomas,
can cause morbidity and mortality, and multiple tubers
results in refractory seizures and exacerbation of men-
tal retardation. Thus, urgent therapy is required for
TS. Here, we demonstrate in a validated preclinical
model a nearly complete tumor inhibition with a com-
bination of two FDA-approved drugs (rapamycin and
imatinib) targeting two distinct signaling pathways
(mTORC1 and PDGFRβ, respectively) implicated in
TS-associated neoplasia.
The lack of total blockade by rapamycin is consistent
with the incomplete clinical response of tumors to sys-
temic rapamycin, implying that either additional path-
ways are already present in these tumors, or are induced
by rapamycin monotherapy. High among the candidates
are the PDGFRβ mediated signal pathways, especially
since mTORC1 activation and PDGFRβ signaling have
been shown to have an inverse relationship [18].
Treatment with combination of rapamycin and imati-
nib led to downregulation of PDGFRβ in tsc2ang1 cells,
in a c-cbl-independent manner (data not shown). In
vitro proliferation assays demonstrated an additive effect
of rapamycin and imatinib on tsc2ang1 cells.
Rapamycin has been used as monotherapy in
patients with TS, resulting in benefit only as long as
the patients are exposed to the drug [12]. Our findings
that rapamycin therapy alone does not address PDGFβ
signaling, as well as modest efficacy against Akt activa-
tion are potential reasons for the failure of rapamycin
as monotherapy in solid tumors. In highly malignant
tumors, mTORC1 inhibition has shown to cause a
paradoxical activation of Akt, in part through activa-
tion of mTORC2, which is an Akt kinase [22,23]. We
demonstrate that the combination of rapamycin and
imatinib blocks Akt activation compared with mono-
therapy, and likely accounts for the decrease in tumor
volume. Our findings demonstrate the following. Com-
bination therapy of TS relevant cells with rapamycin
and imatinib results in downregulation of PDGFRβ
and Akt signaling. This decrease is independent of c-
cbl-mediated degradation. Finally, the combination of
rapamycin and imatinib has at least additive activity
against the tsc2ang1 model of TS in vivo. Given that
the combination of these two approved drugs is well
tolerated in vivo, and that rapamycin alone does not
cause long-lasting remissions, this study provides a
rationale for the combination of these two drugs in
humans.
Materials and methods
Generation of murine model of TS
Tsc2ang1 (ATCC CRL 2620) is a murine cell line derived
from a cutaneous sarcoma that arose in the extremity of
a mouse heterozygous for tsc2; these mice develop cuta-
neous sarcomas at a frequency of 10 to 15%. The cells
were cultured in complete DMEM medium supplemen-
ted with 10% FBS (Sigma Aldrich, St Louis, MO).
In vitro proliferation assay
10,000 tsc2ang1 cells per well were plated in 24-well
dishes in triplicate. The next day, fresh medium contain-
ing the compounds or vehicle controls was added. Cells
were incubated at 37° C for 24 h, and cell number was
determined using a Coulter Counter (Hialeah, FL).
Western blot analysis
Lysates of Tsc2ang1 cells treated with vehicle or indi-
cated drugs were prepared in NP-40 lysis buffer (1% NP-
40, 150 mmol/L NaCl, 10% glycerol, 20 mmol/L HEPES,
1 mmol/L phenylmethylsulfonyl fluoride, 2.5 mmol/L
EDTA, 100 μmol/L Na3VO4, and 1% aprotinin). Protein
concentration in cleared lysates was determined using
an Eppendorf BioPhotometer. Samples were resolved
using SDS-PAGE (National Diagnostics) and transferred
to nitrocellulose membranes. The membranes were
blocked with 5% nonfat dry milk in 10 mmol/L Tris/
0.1% Tween 20/100 mmol/L NaCl and incubated with
primary antibodies followed by horseradish peroxidase–
conjugated secondary antibody. The immunoreactive
bands were visualized by enhanced chemiluminescence
(Amersham Biosciences). The antibodies used were:
Phospho-PDGFR- β antibody(Tyr 1021) (Cell signaling
Laboratories); Akt antibody (9272) (Cell signaling La-
boratories), pAKT (4058) antibody (Cell signaling La-
boratories) monoclonal anti-GAPDH antibody (Santa
Cruz L-18 S-48167) was used as a loading control.
Govindarajan et al. Vascular Cell 2012, 4:11 Page 5 of 6
http://www.vascularcell.com/content/4/1/11Matrix metalloproteinase analysis
The presence of MMPs in conditioned media samples
was determined using MMP ELISA Quantikine Kits
(R&D Systems, Inc.). Specimens, standards and reagents
were prepared according to manufacturer's instructions.
Protein concentration was determined via the Bradford
method using bovine serum albumin as the standard as
described previously [24].
In vivo tumor growth
To test the in vivo activity of compounds that inhibit
tsc2ang1 growth in vitro, groups of four nude mice per
compound (or control). We injected 1 million Tsc2ang1
cells s.c. into 4 nude mice in each group. I.p. treatment
with imatinib, rapamycin and imatinib and rapamycin
were conducted for 30 days. Rapamycin and imatinib
were obtained from LC Laboratories (Woburn, MA). Be-
ginning 2 days later, the mice received daily i.p. injec-
tions of vehicle (control), rapamycin (12 mg/kg/day),
imatinib (120 mg/kg/day) or imatinib plus rapamycin.
The compounds were suspended in 0.1 ml of ethanol
and 0.9 ml of Intralipid solution (Fresenius Kabi, Upp-
sala, Sweden) [25]. No local or systemic toxicity was
observed in any of the animals. Injections were given
over a period of 4 weeks, after which the mice were
sacrificed due to overwhelming tumor burden in the
control group. Tumor volume was calculated using the
equation (w
2 xL)0.52, where w(width) represents the
shortest diameter of the tumor.
Statistics
One way ANOVA, and non parametric test were pre-
formed for the tumor volume statistics. We did paramet-
ric analysis when the conditions for ANOVA were
satisfied and in case where conditions are not satisfied
and if the variables are not normally distributed, we con-
ducted corresponding non parametric test and opted to
present results for Wilcoxon test.
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